促红细胞生成素对心血管保护作用的研究进展

Research progress in cardiovascular protection of erythropoietin

促红细胞生成素(EPO)是特异性作用于红系祖细胞的造血生长因子,但新近有证据表明,EPO具有重要的心脏保护功能。啮齿类动物心肌缺血实验显示,EPO能显著降低心肌梗死面积,改善左心室功能;使用EPO治疗合并贫血的慢性心力衰竭(CHF)患者,可显著改善患者的心功能及临床症状。尽管EPO在治疗肾性贫血过程中可能有导致血压增高、血栓形成的危险,但EPO治疗心肌缺血和CHF是安全的。目前,对EPO所介导的细胞内信号转导路径已有所认识,有可能开辟治疗心血管疾病的新途径。

Although it was originally believed that erythropoietin specifically acted on haematopoietical cells, recent evidence demonstrated that EPO can also exert important cardioprotection, lschaemla experiments in rodents＇ hearts showed large infarct reduction and left ventricular dysfunction mitigation when treated with erythropoietin. When anaemia in chronic heart failure patients was treated with erythropoietin, a significant improvement in cardiac function and clinical symptoms was observed. Despite the potential side effects of hypertension and pro-thrombosis in renal anemia patients treated with eryth- ropoietin, studies showed that erythropoietin therapy was safe and effective during myocardial ischaemia and chronic heart failure. At present, some knowledge has been gained on the erythropoietin mediated signaling passage, which may lead to some new therapies for cardiovascular diseases.